CN111587289B - 一种新型药品递送系统及其提供方法 - Google Patents

一种新型药品递送系统及其提供方法 Download PDF

Info

Publication number
CN111587289B
CN111587289B CN201880006448.0A CN201880006448A CN111587289B CN 111587289 B CN111587289 B CN 111587289B CN 201880006448 A CN201880006448 A CN 201880006448A CN 111587289 B CN111587289 B CN 111587289B
Authority
CN
China
Prior art keywords
vlps
composition
drug delivery
pentamer
bbb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201880006448.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111587289A (zh
Inventor
V·德米纳
H·梅宁格
S·索特尼科夫
M·施塔普夫
K·J·科布曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newhealth Pharmaceutical Co ltd
Original Assignee
Newhealth Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newhealth Pharmaceutical Co ltd filed Critical Newhealth Pharmaceutical Co ltd
Publication of CN111587289A publication Critical patent/CN111587289A/zh
Application granted granted Critical
Publication of CN111587289B publication Critical patent/CN111587289B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/22042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880006448.0A 2018-12-18 2018-12-18 一种新型药品递送系统及其提供方法 Expired - Fee Related CN111587289B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2018/085699 WO2020125962A1 (en) 2018-12-18 2018-12-18 A novel drug delivery system and methods providing thereof

Publications (2)

Publication Number Publication Date
CN111587289A CN111587289A (zh) 2020-08-25
CN111587289B true CN111587289B (zh) 2024-04-12

Family

ID=65009711

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201880006448.0A Expired - Fee Related CN111587289B (zh) 2018-12-18 2018-12-18 一种新型药品递送系统及其提供方法
CN201911300544.9A Pending CN111333702A (zh) 2018-12-18 2019-12-17 用于治疗溶酶体贮积病的vlp
CN202080081855.5A Pending CN115135757A (zh) 2018-12-18 2020-10-13 用于提供John Cunningham病毒VLP的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201911300544.9A Pending CN111333702A (zh) 2018-12-18 2019-12-17 用于治疗溶酶体贮积病的vlp
CN202080081855.5A Pending CN115135757A (zh) 2018-12-18 2020-10-13 用于提供John Cunningham病毒VLP的方法

Country Status (12)

Country Link
US (4) US11279938B2 (cg-RX-API-DMAC7.html)
EP (2) EP3688147B8 (cg-RX-API-DMAC7.html)
JP (3) JP6884432B2 (cg-RX-API-DMAC7.html)
CN (3) CN111587289B (cg-RX-API-DMAC7.html)
BR (3) BR112019014209A2 (cg-RX-API-DMAC7.html)
CA (3) CA3049197C (cg-RX-API-DMAC7.html)
DK (1) DK3688147T3 (cg-RX-API-DMAC7.html)
ES (1) ES2933275T3 (cg-RX-API-DMAC7.html)
HU (1) HUE060952T2 (cg-RX-API-DMAC7.html)
PL (1) PL3688147T3 (cg-RX-API-DMAC7.html)
SI (1) SI3688147T1 (cg-RX-API-DMAC7.html)
WO (4) WO2020125962A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526528A (ja) * 2020-05-22 2023-06-21 ノイウェイ ファルマ ゲーエムベーハー 白質ジストロフィーの処置のためのvlp
WO2022227287A1 (zh) * 2021-04-25 2022-11-03 中南大学 Dnj及其衍生物在制备预防和/或治疗肺动脉高压药物中的应用
CN115448980A (zh) * 2021-06-08 2022-12-09 戴德森医疗财团法人嘉义基督教医院 表面链结标靶多肽的类病毒颗粒及其用途
EP4166672A1 (en) 2021-10-15 2023-04-19 NEUWAY Pharma GmbH A novel method for purification of protein- or peptide-based capsules
CN116554279A (zh) * 2022-01-28 2023-08-08 思凯生科有限公司 包含有专一性表达于前列腺细胞的表达质粒的类病毒颗粒及其用途
WO2024079361A1 (en) 2022-10-14 2024-04-18 Neuway Pharma Gmbh A PROTEIN- OR PEPTIDE-BASED CAPSULE (PPC), PREFERABLY A VLP, LOADED WITH A MESSENGER RNA (mRNA) AND A METHOD OF PRODUCTION AND PURIFICATION THEREOF

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104395475A (zh) * 2012-03-06 2015-03-04 生命科学孵化运作有限责任两合公司 基于jcv-病毒样颗粒的新型药物递送系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19543553B4 (de) 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
FR2920158B1 (fr) 2007-08-24 2010-03-12 Centre Nat Rech Scient Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques
EP2554664A1 (de) 2011-08-02 2013-02-06 Life Science Inkubator Verfahren zur Aufreinigung von Virus-ähnlichen Partikeln (VLP)
SG11201609314XA (en) * 2014-05-14 2016-12-29 Esteve Labor Dr Adenoassociated virus vectors for the treatment of lysosomal storage disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104395475A (zh) * 2012-03-06 2015-03-04 生命科学孵化运作有限责任两合公司 基于jcv-病毒样颗粒的新型药物递送系统

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
In vivo siRNA delivery using JC virus-like particles decreases the expression of RANKL in rats;Hoffmann D B et al.;《Molecular Therapy-Nucleic Acids》;第e298页 *
Packaging of small molecules into VP1-virus-like particles of the human polyomavirus JC virus;Goldmann C et al.;《Journal of virological methods》;第第90卷卷(第第90卷期);第85-90页 *

Also Published As

Publication number Publication date
CN111587289A (zh) 2020-08-25
EP3688147A1 (en) 2020-08-05
US20230159938A1 (en) 2023-05-25
PL3688147T3 (pl) 2023-01-09
JP2022551531A (ja) 2022-12-09
WO2021074123A1 (en) 2021-04-22
CN111333702A (zh) 2020-06-26
EP3688147B1 (en) 2022-09-14
JP6884432B2 (ja) 2021-06-09
SI3688147T1 (sl) 2023-03-31
WO2020125962A1 (en) 2020-06-25
JP2020105169A (ja) 2020-07-09
JP2021502951A (ja) 2021-02-04
WO2020126116A1 (en) 2020-06-25
CA3065548A1 (en) 2020-06-18
WO2020126151A1 (en) 2020-06-25
BR112019014209A2 (pt) 2021-09-28
US20230157972A1 (en) 2023-05-25
HUE060952T2 (hu) 2023-05-28
CA3121689A1 (en) 2020-06-25
EP3688147B8 (en) 2022-10-26
CA3049197C (en) 2023-01-03
US20210301302A1 (en) 2021-09-30
ES2933275T3 (es) 2023-02-03
EP4045638A1 (en) 2022-08-24
US11279938B2 (en) 2022-03-22
CN115135757A (zh) 2022-09-30
CA3049197A1 (en) 2020-05-18
US20200224205A1 (en) 2020-07-16
DK3688147T3 (da) 2022-12-19
BR102019026837A2 (pt) 2020-10-27
BR112021010758A2 (pt) 2021-08-31

Similar Documents

Publication Publication Date Title
JP6884432B2 (ja) 新規薬物送達システムおよびそれを提供する方法
US20260028375A1 (en) Polypeptides self-assembling into nanoparticles
JP2023526528A (ja) 白質ジストロフィーの処置のためのvlp
EP3670652A1 (en) Vlp for the treatment of a lysosomal storage disease
HK40035156B (en) A novel drug delivery system and methods providing thereof
HK40035156A (en) A novel drug delivery system and methods providing thereof
CN112336874B (zh) 纳米药物载体及其制备方法和应用
EP4166672A1 (en) A novel method for purification of protein- or peptide-based capsules
WO2024079361A1 (en) A PROTEIN- OR PEPTIDE-BASED CAPSULE (PPC), PREFERABLY A VLP, LOADED WITH A MESSENGER RNA (mRNA) AND A METHOD OF PRODUCTION AND PURIFICATION THEREOF
CN121517527A (zh) 工程化补体因子h相关蛋白及其应用
HK40055544A (en) Polypeptides self-assembling into nanoparticles
HK40055544B (en) Polypeptides self-assembling into nanoparticles
HK1208046A1 (en) A novel drug delivery system based on jcv-vlp
JPWO1999066061A1 (ja) 核酸導入ファージ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20240412